

chain immunoglobulin polypeptide. Support for a fusion polypeptide comprising a P-selectin glycoprotein ligand-1 polypeptide is found in the specification at page 5, line 7-9. Support for a fusion polypeptide comprising a heavy chain immunoglobulin polypeptide is found in the specification at page 5 lines 37-38. The specification recites “the antigenic fusion protein according to the invention is ... an immunoglobulin or part thereof”. It would be well known to one of ordinary skill in the art that the heavy chain is part of an immunoglobulin (See pp 109-111 of Immunology Second Edition, by Janis Kuby, 1994, attached as Exhibit A). Applicant’s assert that the phrases “comprising a P-selectin glycoprotein ligand-1 and “heavy chain immunoglobulin polypeptide” meets the written description requirement of § 112, first paragraph and requests that this rejection be withdrawn.

The Examiner rejected Claim 24 for lack of written description for the phrase “an extracellular portion of a P-selectin glycoprotein ligand-1”. Applicants disagree. Claim 24 has been canceled, however new independent claim 29, and new dependent claims 30- 32 are directed to a fusion polypeptide comprising an extracellular portion of a P-selectin glycoprotein ligand-1, thus this rejection will be addressed with respect to new claims . The specification as filed provides support for a fusion polypeptide comprising an extracellular portion of a P-selectin glycoprotein ligand-1. Specifically, at page 8, lines 6-10 of the specification, Applicants describe the construction of PSGL1/mIgG<sub>2b</sub>. “The muscin/immunoglobulin expression plasmid was constructed by fusing the PCR-amplified cDNA of *the extracellular part of PSGL-1* in frame with a BamH1 site, to the Fc part (hinge, CH2 and CH3) of mouse IgG<sub>2b</sub> carried as an expression cassette in CDM7.” (Emphasis added). Thus, Applicant’s assert that the phrase “extracellular portion of a P-selectin glycoprotein ligand-1” meets the written description requirement of § 112, first paragraph and requests that this rejection as it applies to new claims 29-32 be withdrawn.

The Examiner has rejected claim 25 for lack of written description for the phrase “a region of a heavy chain immunoglobulin polypeptide”. Claim 25 has been canceled. Applicants request this rejection be withdrawn.

The Examiner has rejected claim 28 for lack of written description for the phrase “comprises more Gal $\alpha$ 1,3Gal epitopes than a wild-type P-selectin glycoprotein ligand-1.”. Applicants disagree. The specification as filed provides support for a fusion polypeptide comprising more Gal $\alpha$ 1,3Gal epitopes than a wild-type P-selectin glycoprotein ligand-1.

Specifically, on page 12, lines 23-37, Applicants describe an experiment testing the capacity of Gal $\alpha$ 1,3Gal substituted PSGL1/mIgG<sub>2b</sub> compared to non-Gal $\alpha$ 1,3Gal substituted PSGL1/mIgG<sub>2</sub> to remove Gal $\alpha$ 1,3Gal antibodies from human serum. The results of this experiments (see, FIG. 3) demonstrate that Gal $\alpha$ 1,3Gal substituted PSGL1/mIgG<sub>2b</sub> has a higher absorption capacity for Gal $\alpha$ 1,3Gal antibodies than non-Gal $\alpha$ 1,3Gal substituted PSGL1/mIgG<sub>2b</sub>. This is evident from the decrease in porcine endothelial cell cytotoxicity following absorption. It would be obvious to one skilled in the art that this higher absorption capacity of Gal $\alpha$ 1,3Gal substituted PSGL1/mIgG<sub>2b</sub> for Gal $\alpha$ 1,3Gal antibodies was a direct result of the of the Gal $\alpha$ 1,3Gal substituted PSGL1/mIgG<sub>2b</sub> having more Gal $\alpha$ 1,3Gal epitopes than the non-Gal $\alpha$ 1,3Gal substituted PSGL1/mIgG<sub>2b</sub> (*i.e.*, wild type PSGL1). Thus, Applicant's assert that the phrase "more Gal $\alpha$ 1,3Gal epitopes than a wild-type P-selectin glycoprotein ligand-1" meets the written description requirement of § 112, first paragraph and requests that this rejection as it applies to claims 28 and new claims 33 and 38 be withdrawn.

#### **§ USC 112, First Paragraph Rejection, Enablement**

The Examiner has rejected claims 21- 26, and 28 under 35 USC 112 first paragraph for lack of enablement. The Examiner asserts that the specification does not reasonably provide enablement for a dimerized fusion protein comprising at least a region of a PSGL-1 and at least a region of an immunoglobulin polypeptide because "the specification fails to disclose a definition for 'at least a region.'" (Office action, page 4 line 2). Applicants have amended independent claim 21 (from which 22-26 and 28 depend) to delete the phrase "at least a region". Therefore this rejection is now moot.



## CONCLUSION


Applicants believe that the claims, as amended are in condition for allowance. If the Examiner has any questions, the Examiner is invited to contact the undersigned by telephone.

Respectfully submitted,

**RECEIVED**

AUG 30 2002

TECH CENTER 1600/2900



---

Ivor R. Elrifi, Reg. No. 39,529  
Cynthia Kozakiewicz, Reg. No. 42,764  
Attorneys for Applicant  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, MA 02111  
Tel: (617) 542 6000  
Fax: (617) 542 2241

Dated: May 20, 2002



**Version Marked to Show Changes**

Claim 21 was amended as follows:

21. A dimerized fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide:

(a) comprises [at least a region of] a P-selectin glycoprotein ligand-1; and

(b) is glycosylated by an  $\alpha$ 1,3 galactosyltransferase and

the second polypeptide comprises [at least a region of] an immunoglobulin heavy chain polypeptide.

TRA 1704865v1

RECEIVED  
AUG 30 2002  
TECH CENTER 1600/2900